Ruizendaal Esmée, Tahita Marc C, Geskus Ronald B, Versteeg Inge, Scott Susana, d'Alessandro Umberto, Lompo Palpouguini, Derra Karim, Traore-Coulibaly Maminata, de Jong Menno D, Schallig Henk D F H, Tinto Halidou, Mens Petra F
Department of Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands.
Institut de Recherche en Sciences de la Santé-Unité de Recherche Clinique de Nanoro, (IRSS-URCN), Nanoro, Burkina Faso.
Malar J. 2017 Apr 28;16(1):179. doi: 10.1186/s12936-017-1831-y.
Pregnant women are a high-risk group for Plasmodium falciparum infections, which may result in maternal anaemia and low birth weight newborns, among other adverse birth outcomes. Intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy (IPTp-SP) is widely implemented to prevent these negative effects of malaria. However, resistance against SP by P. falciparum may decrease efficacy of IPTp-SP. Combinations of point mutations in the dhps (codons A437, K540) and dhfr genes (codons N51, C59, S108) of P. falciparum are associated with SP resistance. In this study the prevalence of SP resistance mutations was determined among P. falciparum found in pregnant women and the general population (GP) from Nanoro, Burkina Faso and the association of IPTp-SP dosing and other variables with mutations was studied.
Blood spots on filter papers were collected from pregnant women at their first antenatal care visit (ANC booking) and at delivery, from an ongoing trial and from the GP in a cross-sectional survey. The dhps and dhfr genes were amplified by nested PCR and products were sequenced to identify mutations conferring resistance (ANC booking, n = 400; delivery, n = 223; GP, n = 400). Prevalence was estimated with generalized estimating equations and for multivariate analyses mixed effects logistic regression was used.
The prevalence of the triple dhfr mutation was high, and significantly higher in the GP and at delivery than at ANC booking, but it did not affect birth weight. Furthermore, quintuple mutations (triple dhfr and double dhps mutations) were found for the first time in Burkina Faso. IPTp-SP did not significantly affect the occurrence of any of the mutations, but high transmission season was associated with increased mutation prevalence in delivery samples. It is unclear why the prevalence of mutations was higher in the GP than in pregnant women at ANC booking.
The high number of mutants and the presence of quintuple mutants in Burkina Faso confirm concerns about the efficacy of IPTp-SP in the near future. Other drug combinations to tackle malaria in pregnancy should, therefore, be explored. An increase in mutation prevalence due to IPTp-SP dosing could not be confirmed.
孕妇是恶性疟原虫感染的高危人群,这可能导致产妇贫血和低体重新生儿等不良分娩结局。孕期间歇性预防性使用磺胺多辛 - 乙胺嘧啶(IPTp - SP)被广泛用于预防疟疾的这些负面影响。然而,恶性疟原虫对乙胺嘧啶 - 磺胺多辛的耐药性可能会降低IPTp - SP的疗效。恶性疟原虫二氢蝶酸合酶(dhps,密码子A437、K540)和二氢叶酸还原酶(dhfr,密码子N51、C59、S108)基因中的点突变组合与乙胺嘧啶 - 磺胺多辛耐药性相关。在本研究中,测定了布基纳法索纳诺罗地区孕妇和普通人群中发现的恶性疟原虫对乙胺嘧啶 - 磺胺多辛耐药性突变的流行情况,并研究了IPTp - SP给药及其他变量与突变的关联。
在一项正在进行的试验中,从孕妇首次产前检查(ANC登记)和分娩时采集滤纸血斑,并在横断面调查中从普通人群中采集。通过巢式PCR扩增dhps和dhfr基因,并对产物进行测序以鉴定赋予耐药性的突变(ANC登记,n = 400;分娩,n = 223;普通人群,n = 400)。采用广义估计方程估计患病率,并使用混合效应逻辑回归进行多变量分析。
三重dhfr突变的患病率很高,在普通人群和分娩时显著高于ANC登记时,但它不影响出生体重。此外,布基纳法索首次发现了五重突变(三重dhfr和双重dhps突变)。IPTp - SP对任何突变的发生均无显著影响,但高传播季节与分娩样本中突变患病率增加有关。目前尚不清楚为何普通人群中的突变患病率高于ANC登记时的孕妇。
布基纳法索大量的突变体和五重突变体的存在证实了对IPTp - SP在不久的将来疗效的担忧。因此,应探索其他用于治疗孕期疟疾的药物组合。未证实IPTp - SP给药会导致突变患病率增加。